Recent news headlines have sparked significant concern among those of us in the pulmonary hypertension (PH) and other rare disease communities. The massive budget and staff cuts across multiple federal agencies are particularly troubling, prompting a flurry of conversations both online and in private. As we navigate these challenging…
Read more
Inhibiting an enzyme known as Aurora kinase B (AURKB) significantly improves multiple measures of blood flow in rat models of pulmonary arterial hypertension (PAH), a study suggests. AURKB blockade worked by suppressing the excessive growth of blood vessel muscle cells, which contributes to the narrowing of pulmonary arteries that…
Winrevair (sotatercept) is generally safe and effective for people with pulmonary arterial hypertension (PAH) when given in addition to their standard of care treatment, a pooled analysis of two clinical trials shows. Along with other benefits, the clinical studies — the Phase 2 PULSAR trial (NCT03496207) and…
Get regular updates to your inbox.
